Celltrion said Feb. 26 it has completed steps to ensure its business operations will not be disrupted regardless of how U.S. tariffs are ultimately settled.
In a statement posted on its website titled “Status of U.S. operations and the company’s position on tariff risk,” Celltrion outlined the operating status of its U.S. production facility and its plans.
Celltrion, which acquired U.S. drugmaker Eli Lilly’s plant in Branchburg, New Jersey, late last year, said it finished a full facility inspection and preparations for full-scale operations by the end of January and began contract manufacturing of Lilly products this month.
The company said it has also begun validation procedures to produce Celltrion’s own products. It said it plans to link local production with its direct sales network to build a system to supply locally made products in the United States as soon as possible.
Celltrion also disclosed short- and mid- to long-term responses to tariff uncertainty. In the near term, it said it will rely on a second year’s worth of supply already in the United States. It said it then plans to supply the U.S. market with products made at the Branchburg plant to move away from tariff exposure.
Celltrion said the Trump administration’s tariff policy could change following a U.S. Supreme Court ruling invalidating reciprocal tariffs, but added that it has completed a structural response system by establishing local production and supply capabilities.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.